In this paper, we focus on the efficacy as well as toxicities of CD38 antibodies used both as a single agent and in combination as multiple myeloma treatment. Keywords: CD38; monoclonal antibodies (MoAb); multiple myeloma.
evaluate the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.
The reduction or loss in CD38 cell surface expression is an important mechanism involved in resistance to anti-CD38 MoAbs in Multiple Myeloma . Thus, we next wondered if CD38 induction following
Multiple Myeloma, drug therapy ; Isatuximab, A chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in
Antineoplastic agent; a recombinant humanized anti-CD38 monoclonal antibody. Uses for Daratumumab: Multiple Myeloma.
Antineoplastic, Anti-CD38 antibody Multiple myeloma [DS:H ] Monoclonal antibody CD38 [HSA:952] [KO:K ] hsa , Hematopoietic cell lineage
anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for
➢ Anti-CD38 (Daratumumab / Darzalex for multiple myeloma). –NICE technology appraisal, completed March 2024. There are other drugs currently undergoing trials
These anti-CD38 monoclonal antibodies will be blockbuster drugs and an important component of multiple myeloma treatment.
Comments